- Home
- SOL vs TCRX Comparison
SOL vs TCRX Comparison
Compare SOL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- TCRX
- Stock Information
- Founded
- SOL 2005
- TCRX 2018
- Country
- SOL United States
- TCRX United States
- Employees
- SOL N/A
- TCRX N/A
- Industry
- SOL Semiconductors
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- TCRX Health Care
- Exchange
- SOL Nasdaq
- TCRX Nasdaq
- Market Cap
- SOL 84.6M
- TCRX 98.5M
- IPO Year
- SOL 2008
- TCRX 2021
- Fundamental
- Price
- SOL $1.57
- TCRX $1.38
- Analyst Decision
- SOL Buy
- TCRX Strong Buy
- Analyst Count
- SOL 3
- TCRX 6
- Target Price
- SOL $3.50
- TCRX $9.83
- AVG Volume (30 Days)
- SOL 657.3K
- TCRX 442.7K
- Earning Date
- SOL 03-13-2025
- TCRX 03-05-2025
- Dividend Yield
- SOL N/A
- TCRX N/A
- EPS Growth
- SOL N/A
- TCRX N/A
- EPS
- SOL N/A
- TCRX N/A
- Revenue
- SOL $92,067,000.00
- TCRX $2,816,000.00
- Revenue This Year
- SOL N/A
- TCRX $32.21
- Revenue Next Year
- SOL $45.37
- TCRX $118.35
- P/E Ratio
- SOL N/A
- TCRX N/A
- Revenue Growth
- SOL N/A
- TCRX N/A
- 52 Week Low
- SOL $1.04
- TCRX $1.28
- 52 Week High
- SOL $3.00
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- SOL 47.08
- TCRX 31.10
- Support Level
- SOL $1.62
- TCRX $1.44
- Resistance Level
- SOL $1.73
- TCRX $1.76
- Average True Range (ATR)
- SOL 0.14
- TCRX 0.17
- MACD
- SOL 0.02
- TCRX -0.01
- Stochastic Oscillator
- SOL 69.74
- TCRX 16.39
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.